Focus:
Oncology
-
16 March 2020 News
WPD reports positive data from Berubicin trial to treat glioblastoma
WPD Pharmaceuticals has reported positive data from the Phase I clinical trial of Berubicin drug to treat glioblastoma multiforme (GBM).
-
11 March 2020 News
Targeted Oncology adds Tennessee Oncology to its SAP programme
Cancer care specialist community Tennessee Oncology has joined Targeted Oncology’s strategic alliance partnership (SAP) programme.
-
9 March 2020 News
Research reveals bias when hiring patients for cancer trials
New research has revealed bias and stereotyping among clinical and research professionals who hire patients for cancer clinical trials.
-
9 March 2020 News
BMS’ ELOQUENT-1 Phase III study fails to meet primary endpoint
Bristol Myers Squibb’s (BMS) ELOQUENT-1 Phase III trial evaluating the Empliciti combination in patients with newly diagnosed, previously untreated multiple myeloma has failed to meet the primary endpoint of progression-free...
-
5 March 2020 News
UK firm PsiOxus starts clinical trial with cancer gene therapy NG-641
UK-based biotechnology firm PsiOxus Therapeutics has initiated a clinical trial with NG-641, a four transgene tumour-microenvironment modifying gene therapy, to treat cancer patients.
-
3 March 2020 News
Karyopharm announces positive results from multiple myeloma trial
Karyopharm Therapeutics has announced positive top-line results from the randomised Phase III BOSTON trial on patients suffering from multiple myeloma.
-
2 March 2020 News
Keytruda improves survival in late-stage trial of cHL
Merck’s Keytruda has improved progression-free survival (PFS) in relapsed or refractory classical Hodgkin lymphoma (cHL) patients involved in the Phase III KEYNOTE-204 clinical trial.
-
2 March 2020 News
AbbVie’s venetoclax misses Phase III endpoint in AML patients
AbbVie has reported that the Phase III VIALE-C clinical trial of venetoclax (Venclexta) plus low-dose cytarabine (LDAC) failed to reach the primary goal in patients with acute myeloid leukaemia (AML).
-
28 February 2020 News
Harbour BioMed gets FDA approval for Phase II NPC trial
Harbour BioMed has received the US Food and Drug Administration (FDA) approval to conduct a Phase II clinical trial of HBM9167 to treat nasopharyngeal cancer (NPC).
-
28 February 2020 News
MapKure, BeiGene, and SpringWorks launch Phase I cancer study
MapKure, BeiGene and SpringWorks Therapeutics have initiated a Phase I clinical trial of BGB-3245 for the treatment of advanced or refractory solid tumour patients in Australia.